Evidence map›Paper›PMID 41802222›Full record

ArticleJournal of neuropathology and experimental neurology2026

Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.

Blake A Ebner, Cristiane M Ida, Thomas M Kollmeyer, Robert B Jenkins, Cinthya J Zepeda Mendoza, Caterina Giannini, Jorge A Trejo-Lopez, Aditya Raghunathan

Abstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Blake A EbnerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.ORCID 0000-0001-5778-6727
Cristiane M IdaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.ORCID 0000-0003-2768-2913
Thomas M Kollmeyer
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.ORCID 0000-0002-4049-694X
Cinthya J Zepeda MendozaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.
Jorge A Trejo-LopezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.
Aditya RaghunathanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.ORCID 0000-0001-6198-7441

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In adult-type diffuse gliomas CDKN2A and/or CDKN2B (CDKN2A/B) deletions often co-occur with deletion of MTAP, suggesting that MTAP immunohistochemistry (IHC) may be a surrogate marker of CDKN2A/B status. However, the association between CDKN2A/B and MTAP deletion at the genomic level remains unknown. We assessed CDKN2A/B and MTAP deletions by chromosomal microarray in 333 adult-type diffuse gliomas and performed MTAP IHC on a subset (n = 63). CDKN2A/B and MTAP deletions were detected in 216 and 215 cases, respectively, and were concurrent in 99.5% (215/216). While most tumors with CDKN2A/B homozygous deletion (n = 148) showed concurrent MTAP homozygous deletion (108/148; 73.0%), a subset harbored MTAP heterozygous deletion (39/148; 26.4%). By analyzing the size of the chromosomal alterations, we demonstrate that initial large chromosomal 9p losses result in concurrent heterozygous deletion of CDKN2A/B and MTAP whereas smaller "second hit" deletions leading to homozygous CDKN2A/B deletion do not always encompass the MTAP locus. Discordant CDKN2A/B and MTAP tumors affect the association between MTAP IHC and copy number status of MTAP and CDKN2A/B. These findings suggest that adult-type diffuse gliomas, regardless of IDH status, follow a stereotypic pathway involving concurrent CDKN2A/B and MTAP heterozygous deletion but may diverge for CDKN2A/B and MTAP homozygous deletion.

Indexed as

Brain NeoplasmsCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16Gene DeletionGliomaPurine-Nucleoside PhosphorylaseAdultAgedFemaleHumansMaleMiddle Aged5'-methylthioadenosine phosphorylaseCDKN2B protein, humanCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16Purine-Nucleoside Phosphorylaseadult-type diffuse gliomasastrocytomaCDKN2A/B; glioblastomahomozygous deletionMTAP; oligodendroglioma

Identifiers

PMID41802222
PMCPMC13197127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.